Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy, enabling X-ALD patients to get treatment for their rare genetic disease.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 1700 Owens Street
  • Suite 525
  • San Francisco, CA 94158
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neurovia’s full profile, request a free trial.

Neurovia Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2018 000.00 Completed Out of Business
1. Early Stage VC (Series A) 25-May-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

Neurovia Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Neurovia Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intarcia Therapeutics Venture Capital-Backed Boston, MA 000 00.000 0000000000 0 00.000
00000000 Accelerator/Incubator Backed New York, NY 00 000.00 0000000000 000.00
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
000000 000 Venture Capital-Backed New Haven, CT 0 00.00 00000000000 00.00
To view this company’s complete list of competitors, request access »